Actionable news
0
All posts from Actionable news
Actionable news in NVS: NOVARTIS AG,

SECURITIES AND EXCHANGE COMMISSION

Report of foreign issuer [Rules 13a-16 and 15d-16]

STYLE="font: 10pt Times New Roman, Times, Serif">

UNITED STATES

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

(Commission File No. 1-15024)

____________________

Novartis AG

(Name of Registrant)

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

Basel, September 24, 2015 Novartis announced today that Dr. James (Jay) E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, has been appointed President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis, effective March 1, 2016.

Dr. Bradner succeeds Mark C. Fishman, M.D., who will reach his contractual retirement age in March 2016 after a distinguished 13-year career at Novartis as the leader of the company’s drug discovery and early clinical development efforts.

“Mark has done an outstanding job leading NIBR, and he will be missed. He redefined research at Novartis - recruiting top scientists and clinicians from around the world, putting patient need and disciplined science at the center of our strategy, which has filled our pipeline with new medicines,” said Joseph Jimenez, CEO of Novartis.

“I am confident that Jay will continue this track record of success. He is an accomplished...


More